Centessa Pharmaceuticals plc (CNTA)
CNTA Stock Price Chart
Explore Centessa Pharmaceuticals plc interactive price chart. Choose custom timeframes to analyze CNTA price movements and trends.
CNTA Company Profile
Discover essential business fundamentals and corporate details for Centessa Pharmaceuticals plc (CNTA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 May 2021
Employees
77.00
Website
https://www.centessa.comCEO
Mario Alberto Accardi
Description
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
CNTA Financial Timeline
Browse a chronological timeline of Centessa Pharmaceuticals plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.40.
Dividend declared on 24 Jun 2026
A dividend of $38.00 per share was announced, adjusted to $38.00.
Earnings released on 5 May 2026
EPS came in at -$0.52 falling short of the estimated -$0.38 by -36.84%.
Earnings released on 31 Mar 2026
EPS came in at -$0.48 falling short of the estimated -$0.37 by -29.23%.
Earnings released on 5 Nov 2025
EPS came in at -$0.41 falling short of the estimated -$0.39 by -5.13%.
Earnings released on 12 Aug 2025
EPS came in at -$0.38 falling short of the estimated -$0.35 by -8.57%.
Earnings released on 14 May 2025
EPS came in at -$0.20 surpassing the estimated -$0.35 by +42.86%, while revenue for the quarter reached $15.00m , beating expectations by +600.00%.
Earnings released on 24 Mar 2025
EPS came in at -$0.34 surpassing the estimated -$0.38 by +10.53%, while revenue for the quarter reached $952.25k .
Earnings released on 12 Nov 2024
EPS came in at -$0.37 surpassing the estimated -$0.42 by +11.90%.
Earnings released on 13 Aug 2024
EPS came in at -$0.40 falling short of the estimated -$0.38 by -5.26%.
Earnings released on 13 May 2024
EPS came in at -$0.38 surpassing the estimated -$0.41 by +7.32%.
Earnings released on 28 Mar 2024
EPS came in at -$0.38 surpassing the estimated -$0.44 by +13.64%, while revenue for the quarter reached $6.91m .
Earnings released on 13 Nov 2023
EPS came in at -$0.40 surpassing the estimated -$0.46 by +13.04%.
Earnings released on 14 Aug 2023
EPS came in at -$0.26 surpassing the estimated -$0.43 by +39.53%.
Earnings released on 12 May 2023
EPS came in at -$0.53 falling short of the estimated -$0.41 by -29.27%.
Earnings released on 30 Mar 2023
EPS came in at -$0.45 surpassing the estimated -$0.48 by +6.25%.
Earnings released on 10 Nov 2022
EPS came in at -$0.57 falling short of the estimated -$0.49 by -16.33%.
Earnings released on 10 Aug 2022
EPS came in at -$0.69 falling short of the estimated -$0.56 by -23.21%.
Earnings released on 16 May 2022
EPS came in at -$0.60 surpassing the estimated -$0.70 by +14.29%.
Earnings released on 30 Mar 2022
EPS came in at -$0.68 falling short of the estimated -$0.60 by -13.33%.
Earnings released on 15 Nov 2021
EPS came in at -$0.45 surpassing the estimated -$0.55 by +18.18%.
Earnings released on 16 Aug 2021
EPS came in at -$0.65 surpassing the estimated -$0.73 by +10.96%.
CNTA Stock Performance
Access detailed CNTA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
